The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Intravascular hemolysis and the pathophysiology of sickle cell disease
Open accessAbstract
flow, normoxia to hypoxia, isotonic to hypertonic environment, and acidotic to alkalotic milieu.Multiple components contribute to sickle hemoglobinopathy pathophysiology, including primary components arising from HbS polymerization and secondary components that are downstream effects of the HbS polymer. Understanding how these components' complexity is compounded by genetic and environmental modulation provides insight into the well-known clinical heterogeneity of sickle cell disease (SCD).A cardinal feature of SCD pathogenesis involves inflammation, accompanied by heterocellular leukocyte-platelet-erythrocyte-endothelial adhesive events that trigger vaso-occlusive episodes, acute organ ischemia, and reperfusion injury.Twenty-five years ago, epidemiological studies identified leukocytosis, lower HbF levels, and higher total hemoglobin levels as risk factors associated with increasing incidence of acute painful episodes and acute chest syndrome (ACS) (5).The independent association of high total hemoglobin levels with more pain, ACS events, and osteonecrosis was never mechanistically explained; however, it was implied to be a result of increased blood viscosity (Table 1).Recent epidemiological studies found that lower hemoglobin levels and higher intensity of steady-state hemolytic anemia consistently associate with vasculopathic complications of disease, such as stroke, leg ulcers, PH, priapism, and renal failure.This suggests that certain subphenotypes of SCD relate more to hemolytic anemia severity rather than sickle vaso-occlusion.The reader is referred to recent reviews describing the exceptional strides made in understanding the roles of red cell rigidity (6), inflammation, and cell adhesion in sickle vaso-occlusion (7-9).Here, we review the complementary role of intravascular hemolysis and anemia.Hemolysis is a fundamental feature of sickle cell anemia that contributes to its pathophysiology and phenotypic variability.Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.Nitric oxide (NO) is inactivated by cell-free hemoglobin in a dioxygenation reaction that also oxidizes hemoglobin to methemoglobin, a non-oxygen-binding form of hemoglobin that readily loses heme.Circulating hemoglobin and heme represent erythrocytic danger-associated molecular pattern (eDAMP) molecules, which activate the innate immune system and endothelium to an inflammatory, proadhesive state that promotes sickle vaso-occlusion and acute lung injury in murine models of sickle cell disease.Intravascular hemolysis can impair NO bioavailability and cause oxidative stress, altering redox balance and amplifying physiological processes that govern blood flow, hemostasis, inflammation, and angiogenesis.These pathological responses promote regional vasoconstriction and subsequent blood vessel remodeling.Thus, intravascular hemolysis represents an intrinsic mechanism for human vascular disease that manifests clinical complications in sickle cell disease and other chronic hereditary or acquired hemolytic anemias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“As HbF falls and fewer F-cells are protected from HbS polymer damage, the propensity for vascular occlusion and intravascular hemolysis increases with the release of heme products into the circulation that scavenge nitric oxide causing endothelial damage and vasculopathy.[57][58][59]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Once released, IL-1β binds to IL-1 receptor (IL-1R) on leukocytes and vascular cells, promoting a cascade of downstream events that lead to activation of neutrophils and platelets and upregulation of E-selectin, P-selectin, VCAM-1, ICAM-1, and chemokines such as IL-8 in endothelial cells, all of which promote vaso-occlusion (14, 17) (Figure 1).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaso-occlusion contributes to ischemia-reperfusion injury, which, along with release of eDAMPs, promotes the progression of sterile inflammation (Figure 1d) in SCD (14, 17, 18).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in adults with SCD lend further support to the role of hemolysis by showing a link between the hyperhemolysis phenotype of SCD and stroke risk (17).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Unequal protection by HbF across the gamut of sickle cell disease complications might be partially explained by differences in the pathophysiologic roots of these complications.57,58”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Acute painful episodes and acute chest syndrome are a result of sickle vasoocclusion; HbF has the most noticeable beneficial effect on these subphenotypes.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Priapism, nephropathy, and sickle vasculopathy are associated with hemolysis.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in Patients with Primary Pulmonary Hypertension
D’Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. Μ., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,488
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“Mortality Increases risk (19, 39, 42, 47, 49, 64, 188) Protective (189) Protective (190)”
Self-citationCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
Rother, R. P., Bell, L. B., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,565
Self-citationPain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citationCastro, O. L., Brambilla, D. J., Thorington, B. D., Reindorf, C. A., Scott, R., GILLETTE, P. N., Vera, J., & Levy, P. S. (1994) · Blood · doi:10.1182/blood.v84.2.643.643 · Cited by 805
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1038/nm1202-799 · DOI · Paper page
Cited by
Sorted by citations
Items 401–500 of 746
Silva, F. H., Fertrin, K. Y., Alexandre, E. C., Calmasini, F. B., Franco‐Penteado, C. F., & Costa, F. F. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249581 · Cited by 5
Haemolysis in sickle cell anaemia: effects of polymorphisms in α‐globin gene regulatory elements
Milton, J. N., Mohammed, E. S. E., & Steinberg, M. H. (2019) · British Journal of Haematology · doi:10.1111/bjh.15852 · Cited by 5
Self-citationNovel clinical care models for patients with sickle cell disease
Bartolucci, P. (2024) · Hematology · doi:10.1182/hematology.2024000586 · Cited by 4
Bernardo, V. S., Torres, F. F., Zucão, A. C. A., Chaves, N. A., Santana, I. L. R., & da Silva, D. G. H. (2025) · Tissue and Cell · doi:10.1016/j.tice.2024.102717 · Cited by 4
Alterations in the humoral immunophenotype in sickle cell disease
Sampino, E. V., Bonal, D. M., Chorzalska, A. D., Morgan, J., Nguyen, L., Yu, C., Rodriguez, A., Vito, R. D., Pels, S. G., Sprinz, P. G., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20089 · Cited by 4
Clinical and Genetic Predictors of Sickle Cell Nephropathy: A Global Systematic Review
Banda, K., Nguweneza, A., Mnika, K., Nembaware, V., Chagaluka, G., & Wonkam, A. (2025) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100251359276 · Cited by 4
Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review
van der Veen, S., Jans, J. J. M., van Beers, E. J., Biemond, B. J., Bartolucci, P., Boaro, M. P., Gimbert, A. C., Colombatti, R., D’Agnolo, M., Fijnvandraat, K., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101338 · Cited by 5
Low bone mineral density and pain impact in adults with sickle cell disease
Adesina, O., Voutsinas, J. M., Wu, Q. V., Teos, L. Y., Rokni, M., Nalbant, H., Nardo, L., Wun, T., & Zemel, B. S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015957 · Cited by 4
Tyo, M. A., Олегович, К. Н., Podoksenov, Y. K., Mukhomedzyanov, А. V., Маслов, Л. Н., & Kozlov, B. N. (2023) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2022-592 · Cited by 4
Athul, K. K., Maity, S., Pareek, N., Kar, P., Maiti, P., & Bhuniya, S. (2024) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2024.115727 · Cited by 4
Gene-environmental influence of space and microgravity on red blood cells with sickle cell disease
Igbineweka, N. E., & van Loon, J. J. W. A. (2024) · npj Genomic Medicine · doi:10.1038/s41525-024-00427-7 · Cited by 6
Yarak, N., Khoury, J. E., Coloby, P. J., Bart, S., & Abdessater, M. (2024) · Basic and Clinical Andrology · doi:10.1186/s12610-024-00237-y · Cited by 4
Hämoglobinopathien als Herausforderung der Migrantenmedizin
Cario, H., & Lobitz, S. (2018) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-018-0544-9 · Cited by 4
Primary polymerization prevention
Steinberg, M. H. (2019) · Blood · doi:10.1182/blood-2019-02-898767 · Cited by 4
Self-citationHIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response
Nekhai, S. A., & Kumari, N. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2054799 · Cited by 5
Pharmacogenomics of Hydroxyurea Therapy and Fetal Hemoglobin Levels in Sickle Cell Anemia
Sales, R. R., Nogueira, B. L., & Luizon, M. R. (2022) · Pharmacogenomics · doi:10.2217/pgs-2022-0050 · Cited by 4
Emerging functional microfluidic assays for the study of thromboinflammation in sickle cell disease
An, R., & Gurkan, U. A. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000731 · Cited by 4
Weller, J. M., Lampmann, T., Asoglu, H., Schneider, M. B., Ehrentraut, S., Lehmann, F., Güresir, E., Dorn, F., Petzold, G. C., Vatter, H., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1156505 · Cited by 4
Lisk, C., Cendali, F. I., Pak, D. I., Swindle, D. C., Hassell, K. L., Nuss, R., George, G., Davizon‐Castillo, P., Buehler, P. W., D’Alessandro, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1149005 · Cited by 4
Gene expression changes in sickle cell reticulocytes and their clinical associations
Zhang, X., Song, J., Shah, B. N., Han, J., Hassan, T., Miasniakova, G., Sergueeva, A., Nekhai, S. A., Machado, R. F., Gladwin, M. T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40039-2 · Cited by 4
Self-citationvan Vuren, A. J., Minniti, C. P., Mendelsohn, L. G., Baird, J. H., Kato, G. J., & van Beers, E. J. (2021) · American Journal of Hematology · doi:10.1002/ajh.26243 · Cited by 4
Self-citationGlycA is not a useful biomarker of inflammation in sickle cell disease
Weisman, J. K., Meeks, D., Mendelsohn, L. G., Remaley, A. T., Sampson, M. L., Allen, D. T., Nichols, J., Shet, A. S., & Thein, S. L. (2018) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12907 · Cited by 4
Gbotosho, O. T., Ghosh, S., Kapetanaki, M. G., Lin, Y., Weidert, F. L., Bullock, G. C., Ofori-Acquah, S. F., & Kato, G. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16129 · Cited by 4
Self-citationYurtsever, N., Tong, N., Geetha, S. D., Nandi, V., & Shi, P. A. (2024) · Transfusion · doi:10.1111/trf.18044 · Cited by 4
Update on the prevalence and pathophysiology of sickle cell priapism: a narrative review
Akakpo, W., & Burnett, A. L. “. (2025) · International Journal of Impotence Research · doi:10.1038/s41443-025-01026-5 · Cited by 3
Trends in hemolytic anemia-related mortality in the United States from 1999-2022
Tuin, A. M., Diehl, T., Billion, T., Mirza, M. M., Tauseef, A., & Jabbar, A. B. A. (2025) · Frontiers in Hematology · doi:10.3389/frhem.2025.1560766 · Cited by 3
Podocyte dysfunction driven by heme in sickle-cell nephropathy
Ali, C. B., Morel, A., Morvan, M., Moktefi, A., Nguyen, K., Wynsberghe, M. V., Sakhi, H., Bartolucci, P., Audard, V., & Hénique, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-09220-7 · Cited by 3
Fogliazza, F., Berzieri, M., Carbone, G., Ciriaco, D., & Esposito, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238599 · Cited by 3
Rethinking Sickle Cell Disease as a Systemic Vasculopathy
DuPont, M., Galadanci, N. A., Patel, R. V., Lebensburger, J. D., & Kanter, J. (2026) · Cells · doi:10.3390/cells15040326 · Cited by 5
Nguefang, G., Boateng, S., Gyabaah, S., Issaka, Y., Mekontso, J. G. K., Landa, E. L., Eze, E., & Njei, B. M. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04322-5 · Cited by 3
Gangji, A., Masamu, U., Mgaya, J., Ndunguru, J., Jonathan, A., Minja, I. K., Makani, J., Balandya, E., Ruggajo, P., & Nkya, S. W. (2021) · Tanzania Journal of Science · doi:10.4314/tjs.v47i3.25 · Cited by 3
Elevated homocysteine and crises state in patients with sickle cell anemia
Orolu, A. K., Adeyemo, T. A., & Akanmu, A. S. (2022) · Journal of Clinical Sciences · doi:10.4103/jcls.jcls_33_22 · Cited by 3
Cook, L. S. (2022) · Journal of Infusion Nursing · doi:10.1097/nan.0000000000000491 · Cited by 3
Szalai, Z., Berkó, A. M., Bódi, N., Hermesz, E., Ferencz, Á., & Bagyánszki, M. (2023) · Applied Sciences · doi:10.3390/app13179920 · Cited by 3
Impact of Sickle Cell Disease on Academic Performance: A Cross Sectional Study
Alsalman, M., AlHaddad, S. M., Alibrahim, I., Alabdullah, A. I., Almutawa, M., Alhamam, A., & Albaqshi, M. A. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s434750 · Cited by 3
Alp, G., Öztaş, Y., Yalçınkaya, A. S., Ozel, S., Yıldırım, N., & Ünal, S. (2024) · Lipids · doi:10.1002/lipd.12389 · Cited by 3
Romana, M., Laurance, S., Hardy‐Dessources, M., Claër, L., Ravion, S., Dorgham, K., Garnier, Y., Kuznicki, L., Tarer, V., Tressières, B., et al. (2024) · HemaSphere · doi:10.1002/hem3.70030 · Cited by 3
Li, N., Song, J., Yang, Y., Huang, X., Tian, Y., Chen, B., Lin, L., & Qin, Z. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167600 · Cited by 3
Silva, J. A. F., Gotardo, É. M. F., Chweih, H., Miguel, L. I., Ferreira, W. A., Hedlund, B. E., Elford, H. L., Leonardo, F. C., Costa, F. F., & Conran, N. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102404 · Cited by 3
Cardiac causes of hypoxia in sickle cell disease
Noronha, S. A. (2020) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2019.101192 · Cited by 4
How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains
Deidda, F., Graziano, T., Amoruso, A., Prisco, A. D., Pane, M., Piano, M. D., & Mogna, L. (2020) · Journal of Probiotics & Health · doi:10.35248/2329-8901.20.8.216 · Cited by 3
Resende, M. B. S., Ferrari, T. C. A., de Araújo, C. G., Vasconcelos, M. C. M., Tupinambás, J. T., Dias, R. C. T. M., Barros, F. C., Januário, J. N., Barbosa, M. M., & Nunes, M. C. P. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-020-01924-3 · Cited by 3
Can red blood cell function assays assess response to red cell-modifying therapies?
White, J., Lancelot, M., Gao, X., Tarasev, M., Chakraborty, S., Emanuele, M., & Hines, P. C. (2021) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-200944 · Cited by 3
Elhawary, E. E., Khedr, S. F., Nagy, H. M., El-Bradey, M. H., & Elshanshory, M. R. (2022) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002435 · Cited by 3
Peroxiredoxin‐2 recycling is slower in denser and pediatric sickle cell red cells
Oh, J., Bae, C. Y., Kasztan, M., Pollock, D. M., Russell, R. T., Lebensburger, J. D., & Patel, R. P. (2022) · The FASEB Journal · doi:10.1096/fj.202200052r · Cited by 3
Renovascular involvement of systemic vascular disease: a pictorial review
Qaseem, Y., Cassidy, F. H., Aganović, L., Purysko, A. S., Mirza, S., & Vahdat, N. (2022) · Abdominal Radiology · doi:10.1007/s00261-022-03591-5 · Cited by 3
Leg Ulcers in Sickle Cell Disease: A Multifactorial Analysis Highlights the Hemolytic Profile
Santos, E. D. C., Santana, P. V. B., de Jesus, L. L. S., Melo, G. I. V., Yahouédéhou, S. C. M. A., da Guarda, C. C., Santiago, R. P., Fiuza, L. M., Carvalho, S. P., dos Santos, L. O., et al. (2023) · Hematology Reports · doi:10.3390/hematolrep15010013 · Cited by 5
Ahmed, S. G., & Ibrahim, U. A. (2023) · Nigerian Journal of Basic and Clinical Sciences. · doi:10.4103/njbcs.njbcs_55_22 · Cited by 3
“Severity” in adult sickle cell disease
Steinberg, M. H., & Gladwin, M. T. (2023) · American Journal of Hematology · doi:10.1002/ajh.27024 · Cited by 3
Self-citationIn-depth structure-function profiling of the complex formation between clotting factor VIII and heme
Hopp, M.-T., Ugurlar, D., Pezeshkpoor, B., Biswas, A., Ramoji, A., Neugebauer, U., Oldenburg, J., & Imhof, D. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.04.006 · Cited by 3
Updates in Pediatric Sickle Cell Lung Disease
Gillespie, M. L., Afolabi‐Brown, O., Machogu, E. M., Willen, S. M., & Kopp, B. T. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.02.022 · Cited by 3
Sahu, T. A., Jagzape, A. T., Sinha, M., Sinha, R., & Verma, H. K. (2025) · World Journal of Virology · doi:10.5501/wjv.v14.i2.101693 · Cited by 3
Vasomotor hyperresponsiveness in SCD
Brousse, V. A. M., & Connes, P. (2020) · Blood · doi:10.1182/blood.2020007070 · Cited by 3
COVID-19 and Sickle Cell Disease: a new challenging dilemma in an old disease
Costa, M., Corrêa, M. S. M., Ferreira, A. L. C. G., Pedrosa, E. N., da Silva, F. A. C., & de Souza, A. I. (2021) · Revista Brasileira de Saúde Materno Infantil · doi:10.1590/1806-9304202100s100018 · Cited by 3
Runge, A. S., Brazel, D., & Pakbaz, Z. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1954285 · Cited by 3
Acute Pancreatitis as a Complication of Sickle Cell Anaemia
Moori, P. L., Dosis, A., Ahmad, Z., Kausar, A., & Triantafyllopoulou, D. (2018) · Reports — Medical Cases Images and Videos · doi:10.3390/reports1030019 · Cited by 3
Exercise training: a prescription for sickle-cell disease?
Kato, G. J. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30178-9 · Cited by 3
Self-citationNouraie, M. S., Zhang, X., Srisuwananukorn, A., Machado, R. F., Gordeuk, V. R., Gladwin, M. T., & Saraf, S. L. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201911-840rl · Cited by 3
Self-citationYalamanoglu, A., Dubach, I. L., Schulthess-Lutz, N., Ingoglia, G., Swindle, D. C., Humar, R., Schaer, D. J., Buehler, P. W., Irwin, D. C., & Vallelian, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627944 · Cited by 3
Association between pulmonary function and cardiac enzymes in sickle cell disease.
Antwi‐Boasiako, C., Asare, M. M., Baba, I., Doku, A., Adutwum-Ofosu, K. K., Hayfron-Benjamin, C. F., Asare, C. P., Aryee, R., Dankwah, G. B., & Ahenkorah, J. (2021) · PubMed Central · Cited by 3
Adawi, E. A., Ghanem, M. A., Ghanem, A. M., Safan, M. A., Elsayed, M. G., & Ageel, M. (2022) · World Journal of Pediatric Surgery · doi:10.1136/wjps-2021-000358 · Cited by 3
Gladwin, M. T., Kato, G. J., & Machado, R. F. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202509-2289ed · Cited by 3
Self-citationHemolysis and innate immunity contribution to sickle cell disease pathophysiology
Maciel, T. T., Rignault‐Bricard, R., Allali, S., & Hermine, O. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005751 · Cited by 2
Ghazaiean, M., Darvishi‐Khezri, H., Najafi, B., Karami, H., & Kosaryan, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318751 · Cited by 3
Impact of blueberry extract on hematological response in phenylhydrazine-induced hemolytic anemia
Drosdowski, D., Türck, P., Tasca, S., Rosa, G. D. L., Guzzo, E. F. M., Bianchi, S. E., Coitinho, A. S., Carraro, C. C., Belló‐Klein, A., de Castro, A. L., et al. (2025) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2025.103744 · Cited by 2
George, P. E., Kalmus, G., Lipscomb, J., Howard, D. H., Kopp, B. T., Lam, W. A., & Ebelt, S. (2025) · JCI Insight · doi:10.1172/jci.insight.190648 · Cited by 2
Lindemann, P., & Hopp, M.-T. (2025) · ChemBioChem · doi:10.1002/cbic.202500636 · Cited by 2
Thrombomodulin protects against acute vascular and multiorgan injury in sickle cell disease
Ren, G., Fraidenburg, D. R., Setty, S., Chen, J., Gonzales, J., Ruiz, M. A., Ivy, Z. K., Eskandari, N., Minshall, R. D., Lash, J. P., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.193884 · Cited by 2
Liu, Y., Shayo, S., Su, S., Bao, W., Zhong, H., Murakhovskaya, I., Lobo, C. A., An, X., Manwani, D. G., Shi, P. A., et al. (2026) · Blood · doi:10.1182/blood.2025031060 · Cited by 2
de Ligt, L. A., Thakoerdin, S. R., Zwolsman, M., Stegemann, G., Matlung, H. L., Kuijpers, T. W., Biemond, B. J., Fijnvandraat, K., van Bruggen, R., & Nur, E. (2026) · American Journal of Hematology · doi:10.1002/ajh.70193 · Cited by 2
CD39 polymorphism enables lung thrombosis in sickle cell disease
Brzóska, T., Kaminski, T. W., Katoch, O., Menchikova, E. V., Alagbe, A. E., Tashbook, S. E., Tofovic, S. P., Jonassaint, J., Croix, C. M. S., Watkins, S. C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68396-2 · Cited by 2
Self-citationMunoz, C. J., Pires, I. S., Lucas, D., Muller, C. R., Martinez, J., Gopal, S., Palmer, A. F., & Cabrales, P. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018529 · Cited by 2
Abdollahi, M., Rahaiee, S., Nami, Y., Khelghatibana, F., Ma’mani, L., & Sadeghi, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-39603-3 · Cited by 2
Myeloperoxidase in the pathogenesis of sickle cell disease
Biernat, M. M., Camp, O. G., Awonuga, A. O., Abu‐Soud, H. M., Chatzicharalampous, C., Kofinas, G., & Kofinas, J. D. (2026) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2026.110800 · Cited by 2
Hassanein, A., & Akhtar, S. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2650021 · Cited by 2
Stiffler, M., Seibert, E., Lin, C.-W., Panigrahi, S., Moore, P. K., Moorman, M. L., Callcut, R. A., Reynolds, J. D. H., Remy, K. E., & Ross, J. T. (2026) · Journal of Surgical Research · doi:10.1016/j.jss.2026.03.054 · Cited by 2
Bradach, D., Calderón-Salavarría, K., Diaz‐Arribasplata, S., Almahdi, R. S. I., Mavus, N. B., Sangaraju, S. L., Sam, A. A., Mohamed, M. S., Brutus, C., Poojary, P. S., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70206 · Cited by 2
Pavitra, E., Kumbhakar, M., Kim, B., Gupta, V. S., Gupta, P., Lee, J., Han, Y.-K., Bhaskar, L. V., Raju, G. S. R., & Huh, Y. S. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.04.003 · Cited by 2
Arterial iron regulates vasodilation during anemia via endothelial holo-α-globin
Dunaway, L. S., Nyshadham, S., Loeb, S. A., O’Donnell, B. L., Abib, N. A., Schug, W. J., Juśkiewicz, Z. J., Luse, M. A., Stahl, M. E., Sveeggen, T. M., et al. (2026) · Blood · doi:10.1182/blood.2025032905 · Cited by 2
Kaspar, C. D. W., Ghosh, S., Lo, M., McClish, D. K., Sisler, I. Y., Newlin, J., Feig, D. I., & Smith, W. B. (2019) · Annals of Nephrology · doi:10.36959/832/398 · Cited by 2
Alauddin, H. (2020) · Medicine & health · doi:10.17576/mh.2020.1501.10 · Cited by 2
Hemostatic Alteration in Sickle Cell Disease
Alhawiti, N. M. (2021) · King Khalid University Journal of Health Sciences · doi:10.4103/kkujhs.kkujhs_7_21 · Cited by 2
Alekhin, Y. N., Sergeevich, Z. M., & Nikonenko, G. V. (2022) · International Journal of Veterinary Medicine · doi:10.52419/issn2072-2419.2022.1.110 · Cited by 2
Noomuna, P., Hausman, J. M., Sansoya, R., Kalfa, T. A., Risinger, M. A., & Low, P. S. (2022) · The FASEB Journal · doi:10.1096/fj.202100809rr · Cited by 2
Vascular Effects of the Fetal Hemoglobin Inducer Agent 3-(1,3-Dioxoisoindolin-2-yl) Benzyl Nitrate
Terroni, B., de Moraes, L. H. O., Pavan, A. R., Rodrigues, G. J., & dos Santos, J. L. (2022) · Pharmaceuticals · doi:10.3390/ph15111311 · Cited by 2
Tambunan, B. A., Ugrasena, I. D. G., & Aryati, A. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s393134 · Cited by 2
(2024) · Hematology and Disorders · doi:10.58489/2836-3582/011 · Cited by 2
Involvement of haptoglobin in disease development
Tuono, R. D. M., Louokdom, J. S., Chetcha, B. C., Magoua, L. M. B., Nya, P. C. B., Pieme, C. A., & Tagny, C. T. (2024) · World Journal of Hematology · doi:10.5315/wjh.v11.i2.94171 · Cited by 2
Freire, A., Charola-Ramos, L., González-Guerra, E., Gonçalves, J., Rocha, V., Afreixo, V. M. A., Martínez‐Carretero, E., & Raya, J. M. (2024) · Anemia · doi:10.1155/2024/1687917 · Cited by 2
Catella, J., Turpin, E., Connes, P., Nader, É., Carin, R., Martin, M., Rezigue, H., Nougier, C., Dargaud, Y. G., Josset‐Lamaugarny, A., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19785 · Cited by 2
Advanced Bio-sensing Technologies for Sickle Cell Disease Diagnosis
Sharma, U., & Upadhyay, L. S. B. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01584-3 · Cited by 2
Zare, P., Ahmadkhani, A., Taherifard, E., Apelian, S., Behjoo, H., & Taherifard, E. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31585 · Cited by 2
Brook, A., Baynes, G. C., Scargill, J., Evangelinos, A., Brennan‐Richardson, C., Dow, F., Ginsberg, Y., Weissbach, T., Brodszki, J., Hansson, E., et al. (2025) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.18104 · Cited by 2
The long road to Ithaca: a physiologist’s journey
Matalon, S. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00030.2025 · Cited by 2
Parry, C. S., Li, Y., Kwofie, S. K., Valencia, J., Niedermaier, C. A. T., Ramadhar, T. R., Nekhai, S. A., Wilson, M. D., & Butcher, R. J. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.141859 · Cited by 2
de Souza, L. P., Sicoli, J., Saad, S. T. O., & Benites, B. D. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2471864 · Cited by 2
SCD and asthma comorbidity: the potential role of adverse childhood experiences
Pernell, B. M., Perumean‐Chaney, S. E., Washington, T., Deshane, J. S., Epel, E. S., Tita, A., Baskin, M. L., & Levitan, E. B. (2025) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoaf007 · Cited by 2
Gotardo, É. M. F., Brito, P. L., Leonardo, F. C., Costa, R., Soares, R. A., Costa, F. F., & Conran, N. (2025) · British Journal of Haematology · doi:10.1111/bjh.20040 · Cited by 2
Romanello, K. S., da Silva, J. P. M. D. O., Torres, F. F., Teixeira, K. K. L., Domingos, I. F., Arcanjo, G. D. S., Pereira‐Martins, D. A., Araújo, A. D. S., Bezerra, M., Malavazi, I., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06294-1 · Cited by 2
Jue, A., Mirea, L., McGary, A. K., & Williams, S. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71147 · Cited by 2
Metadata
- Authors
- Kato, G. J., Steinberg, M. H., & Gladwin, M. T.
- Affiliations
- University of Pittsburgh (US)
- Boston University (US)
- Corresponding author
- Gladwin, Mark T.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-03-01
- Volume
- 127
- Issue
- 3
- Pages
- 750-760
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5330745
- OpenAlex
- W2592339311
- Semantic Scholar
- 0c9beb4e3a557982862ac3ec381a89baab12ceae
- Cited by
- 748
- References
- 193
- Citations by year
- 2026: 90 · 2025: 81 · 2024: 76 · 2023: 65 · 2022: 116 · 2021: 81 · 2020: 87 · 2019: 76 · 2018: 53 · 2017: 21
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Patient-Centered Outcomes Research Institute
- University of Pittsburgh
- Hemophilia Center of Western Pennsylvania
- National Institutes of Health (HL098032)
- National Heart, Lung, and Blood Institute (R01HL087681, R01HL068970, P01HL103455, RC2HL101212, R01HL121386, U01HL107443, T32HL007501, R01HL125886, R01HL098032, T32HL110849)
- National Institute on Minority Health and Health Disparities (R01MD009162)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Keywords
- intravascular hemolysis, sickle cell disease, free hemoglobin, nitric oxide, methemoglobin, heme, arginase-1, asymmetric dimethylarginine, adenine nucleotides, pulmonary hypertension, inflammation
- MeSH terms
- Anemia, Sickle Cell, Hemolysis, Humans, Methemoglobin, Nitric Oxide, Vascular Diseases, Vasomotor System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
